These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38938736)

  • 1. Sex Differences in Cardiovascular Outcomes and Cholesterol-Lowering Efficacy of PCSK9 Inhibitors: Systematic Review and Meta-Analysis.
    Rivera FB; Cha SW; Aparece JP; Rocimo A; Ong BA; Golbin JM; Alfonso PG; Enkhmaa B; Khan SU; Cainzos-Achirica M; Volgman AS; Navar AM; Shah NP
    JACC Adv; 2023 Nov; 2(9):100669. PubMed ID: 38938736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Imbalzano E; Ilardi F; Orlando L; Pintaudi B; Savarese G; Rosano G
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):318-327. PubMed ID: 36972610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis.
    Moustafa B; Oparowski D; Testai S; Guman I; Trifan G
    J Stroke Cerebrovasc Dis; 2024 Apr; 33(4):107633. PubMed ID: 38336118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis.
    Nagendra L; Mahajan K; Gupta G; Dutta D
    Indian Heart J; 2023; 75(6):416-422. PubMed ID: 37777180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
    Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
    J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials.
    Benhuri B; Ueyama H; Takagi H; Briasoulis A; Kuno T
    Curr Vasc Pharmacol; 2021; 19(4):390-397. PubMed ID: 32767943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
    Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M
    Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
    Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
    PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
    Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
    J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011748. PubMed ID: 28453187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?
    Giglio RV; Muzurović EM; Patti AM; Toth PP; Agarwal MA; Almahmeed W; Klisic A; Ciaccio M; Rizzo M
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231186855. PubMed ID: 37448204
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
    Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY
    J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them?
    Arbel R; Hammerman A; Triki N; Greenberg D
    Int J Cardiol; 2016 Oct; 220():242-5. PubMed ID: 27389448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Initiation of PCSK9 Inhibitor Therapy Versus Placebo in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
    Justino GB; Justino LB; Müller ME; Rocha AV; Mazetto A; Cardoso R; Leucker TM
    Am J Cardiol; 2024 Feb; 213():110-118. PubMed ID: 37875235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strike early-strike strong lipid-lowering strategy with PCSK9i in ACS patients. Real-world evidence from AT-TARGET-IT registry.
    Gargiulo P; Basile C; Galasso G; Bellino M; D'Elia D; Patti G; Bosco M; Prinetti M; Andò G; Campanella F; Taverna G; Calabrò P; Cesaro A; Fimiani F; Catalano A; Varbella F; Corleto A; Barillà F; Muscoli S; Musumeci G; Delnevo F; Giallauria F; Napoli R; Porto I; Polimeni A; Quarta R; Maloberti A; Merlini PA; De Luca L; Casu G; Brunetti ND; Crisci M; Paloscia L; Bilato C; Indolfi C; Marzano F; Fontanarosa S; Buonocore D; Parlati ALM; Nardi E; Prastaro M; Soricelli A; Salvatore M; Paolillo S; Perrone-Filardi P;
    Eur J Prev Cardiol; 2024 May; ():. PubMed ID: 38788773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
    Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
    Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis.
    Tselmin S; Julius U; Weinert N; Bornstein SR; Schatz U
    Atheroscler Suppl; 2019 Dec; 40():38-43. PubMed ID: 31818448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.